Latest Breaking News On - Innoviva specialty - Page 1 : comparemela.com

Innovative Treatment for Gonorrhea: Phase III Trial Shows Promise for Zoliflodacin

Phase III trial of zoliflodacin shows it as effective as current treatments for uncomplicated gonorrhea, highlighting its potential in combating rising antibiotic resistance.

Comunidad autonoma de catalunaMatt ronsheimAlison luckeyEuropean society of clinical microbiologyWorld health organizationAdobe stockEuropean societyClinical microbiologyInfectious diseasesInfection control todayInnoviva specialtySpecialty therapeuticsInnoviva specialty therapeutics

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on.

Hong kongNew zealandRepublic ofUnited statesHarald reinhartMatt ronsheimAcinetobacter baumanniiCenters for diseaseHead of global developmentZai lab limitedZai labSecurities exchangeInnoviva incDrug administrationZai lab forwardExchange commission

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesNew zealandUnited kingdomRepublic ofAcinetobacter baumanniiHarald reinhartMatt ronsheimDrug administrationZai lab limitedHealth organizationCenters for diseaseZai lab new drug applicationEntasis therapeutics incZai labHead of global development

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaComunidad autonoma de catalunaUnited kingdomSarah mcleodDavid pattiAlison luckeyDennis riedlGabrielle kornmanDavid altaracHealth emergency preparednessGlobal antibiotic research development partnershipInnoviva incFoundation in genevaUs centers for diseaseInnoviva specialty therapeutics incInfectious disease global congress

Gonorrhea Is Becoming Drug Resistant Scientists Just Found a Solution

A new antibiotic, zoliflodacin, is as effective as the current standard of care. Its creation may hasten the arrival of other needed antibiotics.

United statesJeanne marrazzoMargaret kozielManica balasegaramRamanan laxminarayanGlobal antibiotic research development partnershipEuropean unionNational institute of allergyPrinceton universityWhy it mattersGlobal antibiotic researchDevelopment partnershipBack storyInnoviva specialtyNational instituteDont know